

Title (en)
TREATMENT OF ENDOCRINE RESISTANT BREAST CANCER

Title (de)
BEHANDLUNG VON ENDOKRINRESISTENTEM BRUSTKREBS

Title (fr)
Traitement d'un cancer du sein résistant à l'endocrine

Publication
EP 2558098 A2 20130220 (EN)

Application
EP 11716500 A 20110415

Priority
• EP 10160113 A 20100416
• EP 2011056003 W 20110415
• EP 11716500 A 20110415

Abstract (en)
[origin: WO2011128434A2] The invention relates to pyrimidylaminobenzamides of formula (I) and other suitable PDGF-R inhibitors, alone or in combination with at least one aromatase inhibitor for the treatment of endocrine resistant breast cancer and to a method of treating warm-blooded animals including humans suffering from endocrine resistant breast cancer by administering to a said animal in need of such treatment an effective dose of a pyrimidylaminobenzamide of formula I alone or in combination with an aromatase inhibitor.

IPC 8 full level
A61K 31/506 (2006.01); **A61K 31/404** (2006.01); **A61K 31/4196** (2006.01); **A61K 31/4439** (2006.01); **A61K 31/445** (2006.01);
A61K 31/5685 (2006.01); **A61K 45/06** (2006.01); **A61P 35/00** (2006.01)

CPC (source: EP)
A61K 31/404 (2013.01); **A61K 31/4196** (2013.01); **A61K 31/4439** (2013.01); **A61K 31/445** (2013.01); **A61K 31/506** (2013.01);
A61K 31/5685 (2013.01); **A61K 45/06** (2013.01); **A61P 15/00** (2017.12); **A61P 35/00** (2017.12)

Citation (search report)
See references of WO 2011128434A2

Citation (examination)
• HUAJUN ZHAO ET AL: "Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer", NEOPLASIA (NEW YORK, N.Y.), 1 March 2010 (2010-03-01), Canada, pages 214 - 223, XP055099078, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/20234815>
DOI: 10.1593/neo.91576
• ANONYMOUS: "Abstract 2920: Experimental and clinical studies reveal the PDGF/Abl pathway as a novel therapeutic target in endocrine-resistant breast cancer -- Weigel et al. 70 (1008): 2920 -- Cancer Research", 15 April 2010 (2010-04-15), XP055099414, Retrieved from the Internet
<URL:http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/70/8_MeetingAbstracts/2920> [retrieved on 20140130]
• MARION T WEIGEL ET AL: "Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer", BREAST CANCER RESEARCH, vol. 14, no. 3, 1 January 2012 (2012-01-01), pages R78 - R78, XP055062856, ISSN: 1465-5411, DOI: 10.1016/j.canlet.2007.12.003

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2011128434 A2 20111020; WO 2011128434 A3 20111222; EP 2558098 A2 20130220; JP 2013525296 A 20130620

DOCDB simple family (application)
EP 2011056003 W 20110415; EP 11716500 A 20110415; JP 2013504289 A 20110415